News from Genzyme, Catalent and Futura – People on the move
Genzyme has made two new additions to its management team with William Sibold, and Rogério Vivaldi.
Former managing director of Biogen Idec's Asia Pacific region Sibold joins the firm as head of multiple sclerosis (MS). He has previously worked on other MS products Avonex and Tysabri.
Whilst Vivaldi, a Genzyme Veteran who has been with the company since 1997, worked his way up the ranks to his previous role as president of the renal and endocrinology business. He will now become head of rare diseases.
Both will join the Genzyme Executive Team.
A spokesperson for the firm said: “The MS and Rare Disease businesses constitute Genzyme's core focus following its integration with Sanofi.”
“Our goal is to build a world-leading multiple sclerosis franchise,” added David Meeker.
Catalent Pharma Solutions has appointed Jonathan Arnold as VP and general manager of sterile technologies.
Arnold once worked as export and customer development manager for Catalent’s RP Scherer UK.
He re-joins the company from Patheon, where his most recent role was chief procurement officer and VP global supply chain.
Catalent’s medication delivery solutions president Barry Littlejohns, said: “We are intent on building upon Catalent’s extensive B/F/S and injectable capabilities to become a leading global partner for biologic, vaccine and liquid dose form innovators worldwide.”
MTI has appointed Ken DePinto as VP of strategic services; a move the firm hopes will aid its growth plans.
As part of his new role, he will work as a as a professional relationship management (PRM) consultant to pharmaceutical brands, and will be responsible for managing client relations.
Prior to joining the company – which specialises in development of professional relationship management programs – DePinto served as VP of business development at BI Worldwide, as well as VP of pharmaceutical analytics and strategy for Harte-Hanks.
Jim Neumann, MTI's Senior VP of strategic services said: “Ken has the unique ability to provide consultative support and solution orientation to help MTI advance its position as a strategic partner with our clients.”
Futura Medical has named GlaxoSmithKline exec John Clarke as its new non-executive chairman.
Before joining the group, Clarke has enjoyed a 35 year career at GSK, culminating in his appointment at president of consumer healthcare – a position he recently abdicated.
At Futura, he replaces William Potter, who will step down from the board in February. He will remain at Futura as chief scientific officer.
Of his new role, Clarke said: “I am particularly impressed by the level of innovation at Futura, by the commercial potential of its late stage products and by the breadth of its product pipeline. I look forward to assisting the company in achieving its true potential.”
Kristina Bloomquist has been promoted to the position of executive director of the Medical Research Institute.
Bloomquist joined Medica's health management team in 1999. She was awarded the job of acting executive director in 2009.
Before beginning her career at Medica, she worked at the Memorial University Medical Center in Savannah Georgia, where she developed operations for a health risk reduction and wellness center.
